EUVIMEDEUVIMED entdecken
Open Access

A single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD

Ulrike Gerdemann iD, Kyle Kimler iD, Matthew R Warren, Connor McGuckin, Ryan A Fleming, Matthew R D'Ambra, Alal Eran, Alexandre Albanese iD, Edward Chen iD, Marlana Winschel, Lorenzo Cagnin iD, Jennifer Lane und 13 weitere

Blood · 28.08.2025 · 146 (9) · 1127-1141

DOI: 10.1182/blood.2024027239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 28.08.2025. Verfasst von Ulrike Gerdemann und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Immunoconjugates, Tumor Necrosis Factor Receptor Superfamily, Member 9. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rapid CD137 upregulation on alloreactive T cells upon allogeneic stimulation suggests that their selective elimination could prevent acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HCT). Here, we developed a novel aGVHD prophylactic regimen consisting of a single dose of an anti-CD137 antibody–drug conjugate (CD137-ADC) administered on the day of transplant without additional immunosuppression. The CD137-ADC depleted both human and nonhuman primate (NHP) activated T cells and proved highly effective in preventing xenogeneic aGVHD in mice receiving human peripheral blood mononuclear cells, as well as in NHP undergoing major histocompatibility complex (MHC)-haploidentical HCT. Flow cytometry analysis of NHP T cells indicated specific depletion of activated PD-1+ CD4 and CD8 T cells, while sparing naïve and PD-1−OX40+ memory T-cell subsets during the first week after HCT. CD137-ADC–treated NHP recipients demonstrated robust hematopoietic and immune reconstitution. Hallmarks of T-cell recovery after CD137-ADC, which were associated with long-term aGVHD-free survival, included reconstitution of CD4 memory T cells expressing TRAIL, terminally differentiated CD8 T cells expressing CX3CR1, and CD4 FoxP3+ regulatory T cells, cell types not expected to be involved in aGVHD pathogenesis. CD137-ADC–treated recipients demonstrated a higher risk of reactivation of rhesus lymphocryptovirus (the rhesus macaque Epstein-Barr virus analog), which was associated with reconstitution of follicular helper T cells, interferon signaling–associated memory, and γδT-cell subsets. This reactivation was controllable with rituximab administration. These results document effective depletion of alloreactive T cells and prevention of aGVHD after a single dose of CD137-ADC, suggesting that clinical translation should be carefully explored.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationImmunoconjugatesTumor Necrosis Factor Receptor Superfamily, Member 9AnimalsMacaca mulattaHumansMiceTransplantation, HomologousAcute DiseaseMaleFemale

Substanzen

ImmunoconjugatesTumor Necrosis Factor Receptor Superfamily, Member 9

Autor:innen und Institutionen

  • Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA.
  • Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Department of Pediatrics, Harvard Medical School, Boston, MA.
  • Cell Discovery Network of Boston Children's Hospital, Boston Children's Hospital, Boston, MA.
  • Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA.
  • Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA.

ORCID-Profile: Ulrike Gerdemann, Kyle Kimler, Alexandre Albanese, Edward Chen, Lorenzo Cagnin, Lev Gorfinkel, Jean Kwun, Susan E Prockop, Bruce R Blazar, Leslie S Kean, Victor Tkachev

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Gerdemann, U., Kimler, K., Warren, M. R., McGuckin, C., Fleming, R. A., D'Ambra, M. R., Eran, A., Albanese, A., Chen, E., Winschel, M., Cagnin, L., Lane, J., Gorfinkel, L., Adams, B., Kwun, J., Lanieri, L., Hoban, M., Lamothe, T. L., Hyzy, S., …, & Tkachev, V. (2025). A single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD. Blood, 146(9), 1127-1141. https://doi.org/10.1182/blood.2024027239

Vancouver

Gerdemann U, Kimler K, Warren MR, McGuckin C, Fleming RA, D'Ambra MR, et al. A single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD. Blood. 2025;146(9):1127-1141. doi:10.1182/blood.2024027239

BibTeX
@article{Gerdemann2025,
  author = {Gerdemann, Ulrike and Kimler, Kyle and Warren, Matthew R and McGuckin, Connor and Fleming, Ryan A and D'Ambra, Matthew R and Eran, Alal and Albanese, Alexandre and Chen, Edward and Winschel, Marlana and Cagnin, Lorenzo and Lane, Jennifer and Gorfinkel, Lev and Adams, Bartley and Kwun, Jean and Lanieri, Leanne and Hoban, Megan and Lamothe, Tahirih L and Hyzy, Sharon and Olson, Lisa M and Panoskaltsis-Mortari, Angela and Prockop, Susan E and Blazar, Bruce R and Kean, Leslie S and Tkachev, Victor},
  title = {A single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD},
  journal = {Blood},
  year = {2025},
  volume = {146},
  number = {9},
  pages = {1127--1141},
  doi = {10.1182/blood.2024027239}
}
Kostenlos starten →